RE: How will this board react15 Nov 2023 13:13
If the data does include case studies (of the patient or patients with significant reduction in STS) then it will have a much larger impact as that is something tangible that your average punter understands.
We already know that the safety and tolerability profile of ava6000 is remarkable and beyond expectations.
We already know from biopsies and pk data (to date) that the platform works and delivers dox to fap rich tumours, sparing healthy tissue.
We already know that early efficacy has been observed.
So it's odd we should be where we are sp wise, but it has been spoken about to death.